An increasing number of surgical treatments are performed for orthopedic pathologies in pets. Procedures such as arthrodesis or Tibial Tuberosity Advancement (TTA) have become reference treatments in cases of fractures or rupture of the cranial cruciate ligament (CCLD). Bone grafts, synthetic bone substitutes or metallic implants are often associated with these surgeries in order to improve bone repair and fusion but have various limitations in terms of availability, pain and risk of infection. Thanks to its properties, BIOCERA-VET ideally meets the characteristics expected by veterinarians in order to limit pain and the risks of infection and to promote bone repair and consolidation.
The clinical indications of BIOCERA-VET - BONE SURGERY - are:
- Corrective osteotomy
- TTA (Tibial Tuberosity Advancement)
- All indications for which bonegrafts are required
Osteosarcoma is a primary tumor of the bone that is the most common cancer in dogs and cats. Amputation of the affected limb is the treatment of choice, but it is not always possible (weakened animals, overweight, having already undergone an amputation, ...). Conservative therapy consisting in the removal of the tumor bone segment while maintaining limb function can be performed. Like amputation, this technique does not prevent cancer development and is often combined with chemotherapy in order to improve the quality of life and prolong the survival of the animal.
BIOCERA-VET provides an alternative of choice to amputation and to conservative treatment. Indeed, the injection of BIOCERA-VET into the bone cavity is intended to limit the pain, to reduce the risk of pathological fracture by reinforcing the structural strength of the affected bone tissue and improving mechanical support.
Osteoarthritis is the most common cause of lameness in pets and affects more than 34 million dogs worldwide. Current treatments combine a conservative approach (weight control and physiotherapy), drugs and surgery aimed at reducing pain and inflammation. These treatments may not be very effective or may be associated with significant side-effects or very invasive.
TheraVet is currently developing new potential treatments for canine – and other species - osteoarthritis. One of these products completed a proof-of-concept clinical study in client-owned dogs and is now evaluated in an European pivotal client-owned clinical trial.
Cranial Cruciate Ligament Deficiency
Cranial cruciate ligament deficiency, affecting over 4 million dogs, is currently managed surgically. Deficiency of the cranial cruciate ligament is often a bilateral condition with increased risk of rupture of the contralateral ligament within 12 to 18 months following the initial diagnosis. Currently, no preventive treatment is available to avoid rupture of the contralateral ligament, which will therefore require a second surgical procedure.
TheraVet is developing a new potential preventive treatment for the cranial cruciate ligament rupture which is currently in preclinical development phase.
Tendon and ligament injuries
Tendon and ligament injuries (TLI) are a common cause of lameness in dogs. These lesions often appear as a result of a trauma or following micro-lesions caused by chronic stress. Currently, conservative treatments such as reduction of physical activity, use of anti-inflammatory drugs or intra-articular administration of steroids are encouraged. However, these treatments may lack effectiveness and are sometimes associated with side-effects. A surgical treatment is an alternative but is the source of frequent post-operative complications.
TheraVet is developing a new potential preventive treatment for tendon and ligament which is currently in preclinical development phase.